肿瘤干细胞标志物CD133在非小细胞肺癌中的表达及临床意义

Expression of Tumor Stem Cell Marker CD133 in Non-small Cell Lung Carcinoma and Its Clinical Significance

【目的】研究肿瘤干细胞标志物CD133在非小细胞肺癌(NSCLC)组织中表达的临床意义。【方法】用免疫组织化学方法检测77例手术切除的NSCLC组织中CD133的表达,分析CD133表达与患者吸烟指数、组织学类型、组织分化程度、淋巴结转移、肿瘤T分期、N分期和患者预后之间的关系。【结果】77例NSCLC患者到随访结束时死亡率72.73%(56/77),术后生存时间1～84(s=19)月、3年生存率为32.47%(25/77);无淋巴结结转移组NSCLC的中位生存时间和3年生存率高于有淋巴结转移组(P<0.05)。CD133阳性表达率51.9%(40/77);CD133的表达与淋巴结转移呈正相关(r=0.246,P<0.05),与患者手术后生存期呈负相关(P<0.05)。COX多因素分析仅癌肿病理类型和CD133蛋白表达为影响生存率的独立因素。【结论】NSCLC的淋巴结转移和病理类型与预后有密切关系;肿瘤干细胞标志物CD133蛋白的表达与NSCLC的淋巴结转移和预后密切相关。

[Objective] To investigate the expression of tumor stem cell marker CD133 in non-small cell lung carcinoma （NSCLC） and its relationship with NSCLC clinical significance. [ Methods] Immunohistochemical staining was used to detect the expression of CD133 in 77 cases of patients with NSCLC. The relationship of the expression of CD133 with smoking index number, histological type, differentiation, lymphoid metastasis, T stage, N stage and survival time of the patients was analyzed. [Results] The death rate, live time （mid-live time）, and three years survival rate of NSCLC patients after operation were 72.73% （56/77）, 1-84（s=19）month, 32.47% （25/77）, respectively. Both mid-live time and survival rate of three years after operation in NSCLC patients were longer in negative lymphonode metastasis group than the positive ones （P 〈 0.05）. Out of 77 cases of NSCLC 40 cases （51.9%） showed positive expression of CD133. The expression of CD133 was associated positively with lymphoid metastasis （r=0.246, P 〈 0.05）, and inversely with survival time （P 〈 0.05）. In a COX multivariate analysis, the survival of NSCLC was significantly influenced by the histological type and expression of CD133. [Conclusion] The prognosis of NSCLC were associated with lymphoid metastasis and histological type. The expression of tumor stem cell marker CD133 was associated with lymphoid metastasis and prognosis in NSCLC.